Drug Profile
Anticancer therapeutic antibody - MorphoSys/Pfizer
Alternative Names: PFE-1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MorphoSys; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA
- 31 Jan 2011 Phase-I clinical trials in Cancer in USA (unspecified route)
- 22 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)